Medicare dropped a confidentiality requirement that banned pharmaceutical companies from publicly discussing drug price negotiations set to begin this fall.
Drugmakers had sued the federal government, arguing that the requirement violated the First Amendment. In initial guidance released in March, Medicare had forbidden the industry from publicly disclosing information on the lower price initially offered by the federal government for drugs targeted under the program, as well as the government's reasons for selecting that price point.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: